<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24509833</PMID><DateCompleted><Year>2014</Year><Month>04</Month><Day>28</Day></DateCompleted><DateRevised><Year>2022</Year><Month>01</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1545-9985</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>3</Issue><PubDate><Year>2014</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Nature structural &amp; molecular biology</Title><ISOAbbreviation>Nat Struct Mol Biol</ISOAbbreviation></Journal><ArticleTitle>More-powerful virus inhibitors from structure-based analysis of HEV71 capsid-binding molecules.</ArticleTitle><Pagination><StartPage>282</StartPage><EndPage>288</EndPage><MedlinePgn>282-288</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nsmb.2769</ELocationID><Abstract><AbstractText>Enterovirus 71 (HEV71) epidemics in children and infants result mainly in mild symptoms; however, especially in the Asia-Pacific region, infection can be fatal. At present, no therapies are available. We have used structural analysis of the complete virus to guide the design of HEV71 inhibitors. Analysis of complexes with four 3-(4-pyridyl)-2-imidazolidinone derivatives with varying anti-HEV71 activities pinpointed key structure-activity correlates. We then identified additional potentially beneficial substitutions, developed methods to reliably triage compounds by quantum mechanics-enhanced ligand docking and synthesized two candidates. Structural analysis and in vitro assays confirmed the predicted binding modes and their ability to block viral infection. One ligand (with IC50 of 25 pM) is an order of magnitude more potent than the best previously reported inhibitor and is also more soluble. Our approach may be useful in the design of effective drugs for enterovirus infections.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>De Colibus</LastName><ForeName>Luigi</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Structural Biology, University of Oxford, The Henry Wellcome Building for Genomic Medicine, Headington, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Wang</LastName><ForeName>Xiangxi</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Science, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spyrou</LastName><ForeName>John A B</ForeName><Initials>JAB</Initials><AffiliationInfo><Affiliation>Division of Structural Biology, University of Oxford, The Henry Wellcome Building for Genomic Medicine, Headington, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kelly</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>School of Molecular and Cellular Biology, Astbury Centre for Structural Molecular Biology, University of Leeds, Leeds, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ren</LastName><ForeName>Jingshan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Structural Biology, University of Oxford, The Henry Wellcome Building for Genomic Medicine, Headington, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grimes</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Structural Biology, University of Oxford, The Henry Wellcome Building for Genomic Medicine, Headington, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Diamond Light Sources, Harwell Science and Innovation Campus, Didcot, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Puerstinger</LastName><ForeName>Gerhard</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Chemistry, University of Innsbruck, Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stonehouse</LastName><ForeName>Nicola</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>School of Molecular and Cellular Biology, Astbury Centre for Structural Molecular Biology, University of Leeds, Leeds, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walter</LastName><ForeName>Thomas S</ForeName><Initials>TS</Initials><AffiliationInfo><Affiliation>Division of Structural Biology, University of Oxford, The Henry Wellcome Building for Genomic Medicine, Headington, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Zhongyu</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>National Institutes for Food and Drug Control, No. 2, TiantanXili, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Junzhi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>National Institutes for Food and Drug Control, No. 2, TiantanXili, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xuemei</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Science, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Science, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rowlands</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>School of Molecular and Cellular Biology, Astbury Centre for Structural Molecular Biology, University of Leeds, Leeds, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fry</LastName><ForeName>Elizabeth E</ForeName><Initials>EE</Initials><AffiliationInfo><Affiliation>Division of Structural Biology, University of Oxford, The Henry Wellcome Building for Genomic Medicine, Headington, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rao</LastName><ForeName>Zihe</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Science, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Structural Biology, School of Medicine, Tsinghua University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stuart</LastName><ForeName>David I</ForeName><Initials>DI</Initials><AffiliationInfo><Affiliation>Division of Structural Biology, University of Oxford, The Henry Wellcome Building for Genomic Medicine, Headington, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Diamond Light Sources, Harwell Science and Innovation Campus, Didcot, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>PDB</DataBankName><AccessionNumberList><AccessionNumber>4CDQ</AccessionNumber><AccessionNumber>4CDU</AccessionNumber><AccessionNumber>4CDW</AccessionNumber><AccessionNumber>4CDX</AccessionNumber><AccessionNumber>4CEW</AccessionNumber><AccessionNumber>4CEY</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>G110525</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G1100525</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G1000099</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>090532/Z</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G100099</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>090532</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G19/3</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>02</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Struct Mol Biol</MedlineTA><NlmUniqueID>101186374</NlmUniqueID><ISSNLinking>1545-9985</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D036022">Capsid Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008024">Ligands</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001665" MajorTopicYN="N">Binding Sites</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002213" MajorTopicYN="N">Capsid</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D036022" MajorTopicYN="N">Capsid Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002626" MajorTopicYN="N">Chemistry, Pharmaceutical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015195" MajorTopicYN="N">Drug Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="N">Enterovirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007093" MajorTopicYN="N">Imidazoles</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020128" MajorTopicYN="N">Inhibitory Concentration 50</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008024" MajorTopicYN="N">Ligands</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011487" MajorTopicYN="N">Protein Conformation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013329" MajorTopicYN="N">Structure-Activity Relationship</DescriptorName></MeshHeading></MeshHeadingList><OtherID Source="NLM">EMS56297</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>7</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>1</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>2</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>2</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>4</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>8</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24509833</ArticleId><ArticleId IdType="mid">EMS56297</ArticleId><ArticleId IdType="pmc">PMC4530014</ArticleId><ArticleId IdType="doi">10.1038/nsmb.2769</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>MCMINN PC. Enterovirus 71 in the Asia-Pacific region: An emerging cause of acute neurological disease in young children. Neurol J Southeast Asia. 2003;8:57&#x2013;63.</Citation></Reference><Reference><Citation>Rossmann MG, et al. Structure of a human common cold virus and functional relationship to other picornaviruses. Nature. 1985;317:145&#x2013;153.</Citation><ArticleIdList><ArticleId IdType="pubmed">2993920</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren J, et al. Picornavirus uncoating intermediate captured in atomic detail. Nature communications. 2013;4:1929.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3709478</ArticleId><ArticleId IdType="pubmed">23728514</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, et al. A sensor-adaptor mechanism for enterovirus uncoating from structures of EV71. Nature structural &amp; molecular biology. 2012;19:424&#x2013;429.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3378640</ArticleId><ArticleId IdType="pubmed">22388738</ArticleId></ArticleIdList></Reference><Reference><Citation>Rotbart HA. Treatment of picornavirus infections. Antiviral research. 2002;53:83&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">11750935</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsang SK, et al. A structurally biased combinatorial approach for discovering new anti-picornaviral compounds. Chemistry &amp; biology. 2001;8:33&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">11182317</ArticleId></ArticleIdList></Reference><Reference><Citation>Phelps DK, Post CB. A novel basis of capsid stabilization by antiviral compounds. Journal of molecular biology. 1995;254:544&#x2013;551.</Citation><ArticleIdList><ArticleId IdType="pubmed">7500332</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsang SK, Danthi P, Chow M, Hogle JM. Stabilization of poliovirus by capsid-binding antiviral drugs is due to entropic effects. Journal of molecular biology. 2000;296:335&#x2013;340.</Citation><ArticleIdList><ArticleId IdType="pubmed">10669591</ArticleId></ArticleIdList></Reference><Reference><Citation>De Palma AM, Vliegen I, De Clercq E, Neyts J. Selective inhibitors of picornavirus replication. Medicinal research reviews. 2008;28:823&#x2013;884.</Citation><ArticleIdList><ArticleId IdType="pubmed">18381747</ArticleId></ArticleIdList></Reference><Reference><Citation>Feil SC, et al. An Orally Available 3-Ethoxybenzisoxazole Capsid Binder with Clinical Activity against Human Rhinovirus. Acs Med Chem Lett. 2012;3:303&#x2013;307.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4025830</ArticleId><ArticleId IdType="pubmed">24900468</ArticleId></ArticleIdList></Reference><Reference><Citation>Pevear DC, Tull TM, Seipel ME, Groarke JM. Activity of pleconaril against enteroviruses. Antimicrobial agents and chemotherapy. 1999;43:2109&#x2013;2115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC89431</ArticleId><ArticleId IdType="pubmed">10471549</ArticleId></ArticleIdList></Reference><Reference><Citation>Shia KS, et al. Design, synthesis, and structure-activity relationship of pyridyl imidazolidinones: a novel class of potent and selective human enterovirus 71 inhibitors. Journal of medicinal chemistry. 2002;45:1644&#x2013;1655.</Citation><ArticleIdList><ArticleId IdType="pubmed">11931618</ArticleId></ArticleIdList></Reference><Reference><Citation>Ke YY, Lin TH. Modeling the ligand-receptor interaction for a series of inhibitors of the capsid protein of enterovirus 71 using several three-dimensional quantitative structure-activity relationship techniques. Journal of medicinal chemistry. 2006;49:4517&#x2013;4525.</Citation><ArticleIdList><ArticleId IdType="pubmed">16854057</ArticleId></ArticleIdList></Reference><Reference><Citation>Plevka P, Perera R, Cardosa J, Kuhn RJ, Rossmann MG. Crystal structure of human enterovirus 71. Science. 2012;336:1274.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3448362</ArticleId><ArticleId IdType="pubmed">22383808</ArticleId></ArticleIdList></Reference><Reference><Citation>Plevka P, et al. Structure of human enterovirus 71 in complex with a capsid-binding inhibitor. P Natl Acad Sci USA. 2013;110:5463&#x2013;5467.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3619292</ArticleId><ArticleId IdType="pubmed">23509286</ArticleId></ArticleIdList></Reference><Reference><Citation>von Itzstein M, et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature. 1993;363:418&#x2013;423.</Citation><ArticleIdList><ArticleId IdType="pubmed">8502295</ArticleId></ArticleIdList></Reference><Reference><Citation>Warren GL, et al. A critical assessment of docking programs and scoring functions. Journal of medicinal chemistry. 2006;49:5912&#x2013;5931.</Citation><ArticleIdList><ArticleId IdType="pubmed">17004707</ArticleId></ArticleIdList></Reference><Reference><Citation>Axford D, et al. In situ macromolecular crystallography using microbeams. Acta crystallographica. Section D, Biological crystallography. 2012;68:592&#x2013;600.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4791750</ArticleId><ArticleId IdType="pubmed">22525757</ArticleId></ArticleIdList></Reference><Reference><Citation>Winn MD, et al. Overview of the CCP4 suite and current developments. Acta Crystallogr D. 2011;67:235&#x2013;242.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3069738</ArticleId><ArticleId IdType="pubmed">21460441</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang CS, et al. Design, synthesis, and antipicornavirus activity of 1-[5-(4-arylphenoxy)alkyl]-3-pyridin-4-ylimidazolidin-2-one derivatives. Journal of medicinal chemistry. 2005;48:3522&#x2013;3535.</Citation><ArticleIdList><ArticleId IdType="pubmed">15887961</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho AE, Guallar V, Berne BJ, Friesner R. Importance of accurate charges in molecular docking: quantum mechanical/molecular mechanical (QM/MM) approach. Journal of computational chemistry. 2005;26:915&#x2013;931.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3920598</ArticleId><ArticleId IdType="pubmed">15841474</ArticleId></ArticleIdList></Reference><Reference><Citation>Walter TS, et al. A plate-based high-throughput assay for virus stability and vaccine formulation. Journal of virological methods. 2012;185:166&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3470038</ArticleId><ArticleId IdType="pubmed">22744000</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodford PJ. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. Journal of medicinal chemistry. 1985;28:849&#x2013;857.</Citation><ArticleIdList><ArticleId IdType="pubmed">3892003</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuttelkopf AW, van Aalten DM. PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. Acta crystallographica. Section D, Biological crystallography. 2004;60:1355&#x2013;1363.</Citation><ArticleIdList><ArticleId IdType="pubmed">15272157</ArticleId></ArticleIdList></Reference><Reference><Citation>Kenakin TP. Pharmacologic Analysis of Drug-Receptor Interaction. Lippincott Raven; 1993. p. 483.</Citation></Reference><Reference><Citation>JosephMcCarthy D, Hogle JM, Karplus M. Use of the multiple copy simultaneous search (MCSS) method to design a new class of picornavirus capsid binding drugs. Proteins. 1997;29:32&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">9294865</ArticleId></ArticleIdList></Reference><Reference><Citation>Joseph-McCarthy D, Tsang SK, Filman DJ, Hogle JM, Karplus M. Use of MCSS to design small targeted libraries: Application to picornavirus ligands. J Am Chem Soc. 2001;123:12758&#x2013;12769.</Citation><ArticleIdList><ArticleId IdType="pubmed">11749532</ArticleId></ArticleIdList></Reference><Reference><Citation>Hiremath CN, Grant RA, Filman DJ, Hogle JM. Binding of the antiviral drug WIN51711 to the sabin strain of type 3 poliovirus: structural comparison with drug binding in rhinovirus 14. Acta crystallographica. Section D, Biological crystallography. 1995;51:473&#x2013;489.</Citation><ArticleIdList><ArticleId IdType="pubmed">15299834</ArticleId></ArticleIdList></Reference><Reference><Citation>Grant RA, et al. Structures of poliovirus complexes with anti-viral drugs: implications for viral stability and drug design. Current biology: CB. 1994;4:784&#x2013;797.</Citation><ArticleIdList><ArticleId IdType="pubmed">7820548</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, et al. Structural and virological studies of the stages of virus replication that are affected by antirhinovirus compounds. Journal of virology. 2004;78:11061&#x2013;11069.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC521849</ArticleId><ArticleId IdType="pubmed">15452226</ArticleId></ArticleIdList></Reference><Reference><Citation>Lentz KN, et al. Structure of poliovirus type 2 Lansing complexed with antiviral agent SCH48973: comparison of the structural and biological properties of three poliovirus serotypes. Structure. 1997;5:961&#x2013;978.</Citation><ArticleIdList><ArticleId IdType="pubmed">9261087</ArticleId></ArticleIdList></Reference><Reference><Citation>Diana GD, et al. A model for compounds active against human rhinovirus-14 based on X-ray crystallography data. Journal of medicinal chemistry. 1990;33:1306&#x2013;1311.</Citation><ArticleIdList><ArticleId IdType="pubmed">2158559</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliver Rev. 1997;23:3&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">11259830</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadfield AT, et al. Structural studies on human rhinovirus 14 drug-resistant compensation mutants. Journal of molecular biology. 1995;253:61&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">7473717</ArticleId></ArticleIdList></Reference><Reference><Citation>Hopkins AL, et al. Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 1. Journal of medicinal chemistry. 2004;47:5912&#x2013;5922.</Citation><ArticleIdList><ArticleId IdType="pubmed">15537346</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>ONLINE METHODS REFERENCES</Title><Reference><Citation>Walter TS, et al. A procedure for setting up high-throughput nanolitre crystallization experiments. I. Protocol design and validation. J Appl Crystallogr. 2003;36:308&#x2013;314.</Citation></Reference><Reference><Citation>Walter TS, et al. A procedure for setting up high-throughput nanolitre crystallization experiments. Crystallization workflow for initial screening, automated storage, imaging and optimization. Acta crystallographica. Section D, Biological crystallography. 2005;61:651&#x2013;657.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159505</ArticleId><ArticleId IdType="pubmed">15930615</ArticleId></ArticleIdList></Reference><Reference><Citation>Otwinowski Z, Minor W. Processing of X-ray diffraction data collected in oscillation mode. Method Enzymol. 1997;276:307&#x2013;326.</Citation><ArticleIdList><ArticleId IdType="pubmed">27754618</ArticleId></ArticleIdList></Reference><Reference><Citation>French S, Wilson K. On the treatment of negative intensity observations. Acta Cryst. A. 1978;34:517&#x2013;525.</Citation></Reference><Reference><Citation>Brunger AT, et al. Crystallography &amp; NMR System (CNS), A new software suite for macromolecular structure determination. Acta Cryst. D. 1998;54:905&#x2013;921.</Citation><ArticleIdList><ArticleId IdType="pubmed">9757107</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicholls RA, Long F, Murshudov GN. Low-resolution refinement tools in REFMAC5. Acta crystallographica. Section D, Biological crystallography. 2012;68:404&#x2013;417.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3322599</ArticleId><ArticleId IdType="pubmed">22505260</ArticleId></ArticleIdList></Reference><Reference><Citation>Cowtan K. Recent developments in classical density modification. Acta crystallographica. Section D, Biological crystallography. 2010;66:470&#x2013;478.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2852311</ArticleId><ArticleId IdType="pubmed">20383000</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleywegt GJ. Dictionaries for Heteros. CCP4/ESF-EACBM Newsletter on Protein Crystallography. 1995:45&#x2013;50.</Citation></Reference><Reference><Citation>Emsley P, Lohkamp B, Scott WG, Cowtan K. Features and development of Coot. Acta crystallographica. Section D, Biological crystallography. 2010;66:486&#x2013;501.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2852313</ArticleId><ArticleId IdType="pubmed">20383002</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen VB, et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta crystallographica. Section D, Biological crystallography. 2010;66:12&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2803126</ArticleId><ArticleId IdType="pubmed">20057044</ArticleId></ArticleIdList></Reference><Reference><Citation>Pettersen EF, et al. UCSF Chimera--a visualization system for exploratory research and analysis. J. Comput. Chem. 2004;25:1605&#x2013;1612.</Citation><ArticleIdList><ArticleId IdType="pubmed">15264254</ArticleId></ArticleIdList></Reference><Reference><Citation>Banks JL, et al. Integrated Modeling Program, Applied Chemical Theory (IMPACT) Journal of computational chemistry. 2005;26:1752&#x2013;1780.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2742605</ArticleId><ArticleId IdType="pubmed">16211539</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed LJM. A simple method of estimating fifty percentage endpoints. The American Journal of Hygene. 1938;27:493&#x2013;497. H.</Citation></Reference><Reference><Citation>Tetko IV, et al. Virtual computational chemistry laboratory - design and description. J. Comput. Aid. Mol. Des. 2005;19:453&#x2013;463.</Citation><ArticleIdList><ArticleId IdType="pubmed">16231203</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>